Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide


Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some


Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that


Director named for Fralin Biomedical Research Institute at VTC Cancer Research Center

An accomplished biomedical engineer who studies the biophysical setting of brain cancer has been named director of the Fralin Biomedical Research Institute at VTC’s Cancer Research Center in Roanoke, Virginia. Jennifer Munson will organize the institute’s Cancer Research Center in Roanoke, while closely collaborating with its Cancer Research Center in Washington, D.C., said Michael Friedlander, Virginia Tech’s vice


BrightSpec Adds Commercial Firepower to its Leadership Team and Board of Directors

BrightSpec, the market leader in Molecular Rotational Resonance (MRR) spectroscopy solutions, announced the appointment of two new executives to drive the commercialization of their growing portfolio of precision instruments and analytical tools. BrightSpec develops and commercializes instruments that harness the power of MRR spectroscopy, an innovative approach to rapidly and definitively characterize the unique three-dimensional


News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture BIO-CAT Announces Safety Study on New Enzyme Addressing High FODMAP Foods

BIO-CAT, an industry-leading enzyme supplier headquartered in Virginia, is excited to announce the publication of a groundbreaking safety clinical trial manuscript featuring its proprietary ingredient, OPTIZIOME® Inulinase  (now marketed as OPTIZIOME® Fructanase), in Gastro Hep Advances. Fructanase, also known as inulinase, was developed to address the unintended consequences of digestive discomfort from certain foods, more


ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive

ReAlta Life Sciences, Inc., a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announced the appointment of Emma Reeve to its Board of Directors, effective immediately. “We are very pleased to welcome Emma Reeve to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta’s Board


CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital


Contraline’s First In-Human Trial Shows Safety with 12-Month Efficacy Signals of the ADAM™ Male Contraceptive Device

Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating the safety and preliminary efficacy of Contraline’s ADAM™, a non-permanent male contraceptive, has had its first patients demonstrate 12 months of efficacy in the study. ADAM™ is a water-soluble, biocompatible, and non-permanent


Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, and HekaBio, headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN). SP163M, a groundbreaking discovery by Serpin Pharma, is set to revolutionize pain management. This novel therapy protects nerves from the damaging effects of


Chandra Briggman is leaving Richmond’s Activation Capital

Chandra Briggman is exiting her role as president and CEO of Richmond’s Activation Capital. The independent authority of Virginia that promotes research, commercialization and innovation ecosystem development in the Richmond region said Monday that Briggman is leaving “to pursue new opportunities to build innovation ecosystems and drive economic development.” She’s been in the role a


Roquette and Bonumose Sign a Global Cooperation Agreement Supporting Tagatose Growth

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, and Bonumose, a pioneer in enzymatic solutions for rare monosaccharide production, are pleased to announce the signing of a Cooperation Agreement that aims to advance the development of tagatose, a natural-origin sweetener with clinically proven health benefits. This collaboration combines Roquette’s


Virginia Catalyst announces Grant Round 16 awarded projects!

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16. “Powerful collaborations


Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on rare and orphan diseases,  announced that it will expand its ongoing Netherton Syndrome clinical studies to include international sites. The first international site will be opened at a research hospital in Saudi Arabia. This hospital is currently treating a number of Netherton patients who


PAK BioSolutions Raises $12 Million Series A to Expand Continuous Biomanufacturing Product Line

PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated continuous manufacturing systems for biologics. The PAK Pilot System is capable of processing 50-500L of cell culture per day, addressing a major segment of the biopharmaceutical


Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential


KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury


Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst


Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises

A tighter venture capital market has affected more than the funding biotechs receive. It’s also changed how early-stage companies structure CEO pay packages, according to Leslie Loveless, CEO and managing partner of Slone Partners, a life sciences and healthcare executive search firm. Because of how funding dipped, she told BioSpace, early-stage biotechs started tying CEO


AMPEL BioSolutions Building Evidence for Prognostic Potential of Lupus Molecular Subtyping Test

AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations. In addition, the company has been conducting a study to see whether different lupus subtypes as defined by its test correlate with


Virginia Medtech Company Is Awarded $13M Contract Continuation from the Navy

NIRSense Inc., headquartered in Richmond, Virginia, won an expansion to a competitively-awarded contract this month to build fieldable physiology monitors for the US Navy. NIRSense has been working with the Department of Defense since 2019 to build medical-grade physiology monitors to support US warfighter safety, performance, and medical care in training and operations. “NIRSense has


Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

Activation Capital announces the launch of Frontier BioHealth, an educational and support program designed to provide highly specialized training, targeted mentorship, and relationship building to help scale pharmaceutical, biotech, medical device, and health-focused consumer products companies. The inaugural four-month program will be critical in bringing research-intense products and companies to market. It will broaden the


Virginia Bio Announces Recipients of its 2024 Outstanding Contributions to Bioscience Award

Every two years, the Virginia Biotechnology Association recognizes individual Virginians for their significant contributions to bioscience and the Virginia biotechnology ecosystem.  On May 17, Jeff Conroy, former CEO of Embody, Inc., and Jim Powers, former CEO of HemoShear were presented with the Outstanding Contributions to Bioscience Award at Virginia Bio’s THRiVE 2024 statewide conference in


SRI earns FDA Orphan Drug Designation for pancreatic cancer

SRI’s Targeted Antigen Loaded Liposomes (TALL) — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation (ODD) for pancreatic ductal adenocarcinoma (PDAC) by the U.S. Federal Drug Administration (FDA). As a result, SRI’s future strategic partners can gain tax credits for qualified clinical trials and potentially receive market exclusivity


Governor Youngkin Announces New VIPC-Led Initiative that Catalyzes and Attracts Investment into Virginia-based, Innovation-driven Startups and Entrepreneurs

Governor Glenn Youngkin announced a new initiative led by Virginia Innovation Partnership Corporation (VIPC) that expands investment and growth opportunities for Virginia-based, innovation-driven startups and entrepreneurial ecosystems throughout the Commonwealth. Leveraging previous Virginia-awarded federal funding from the U.S. Department of Treasury, under its SSBCI Equity/Venture Capital Program, VIPC’s Virginia Invests launches new investment partnerships with an